Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing - Wikidata - wikimedia - TriplyDB

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

http://www.wikidata.org/entity/Q34367423

about

Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing Inborn errors of pyrimidine metabolism: clinical update and therapy Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity New advances in DPYD genotype and risk of severe toxicity under capecitabine.Implementation and utilization of genetic testing in personalized medicine.Neutrophil-guided dosing of anthracycline-cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study.Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer.Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.EHR based Genetic Testing Knowledge Base (iGTKB) Development.DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians.Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience.Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.Important molecular genetic markers of colorectal cancer.microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites.Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing Role of solute carrier transporters in pancreatic cancer: a review.Genomic architecture of pharmacological efficacy and adverse events.Pharmacogenomics of fluorouracil -based chemotherapy toxicity.Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.Personalizing chemotherapy dosing using pharmacological methods.A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer Nuclear receptors and drug metabolism for the personalization of cancer therapy.Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.

P2860

Q26741009-F86C97E4-F22A-408C-9849-6AB811FD2CB5 Q26766244-D757D8BA-D9FF-4700-9C79-83685103AD21 Q26851060-D5231B7E-350C-4C41-85AC-FE452523AF49 Q28079766-37364D72-C0BB-405E-8346-95B1E9AB296B Q28244040-06C4A4B1-2954-4CAF-9CCC-2DAD856E17B2 Q28392069-888916AF-35C1-4D9F-943B-2BF04ACFF9E0 Q28552832-D6475610-4EF1-4726-80EE-C7A50B3A82FE Q28652720-69473A83-D61C-49A5-AD71-77536983D95B Q31058146-FFBC613D-AA55-4911-8B40-AECEC28D8157 Q33418614-E360ABEF-45AD-44A8-8CA7-8790861771B2 Q33576321-D8BFD837-8B67-4171-B9D7-E28815648C9A Q33648195-69331729-A9C5-4170-A06E-BD36166F27A5 Q34147916-B0A6F69F-C494-44B4-8D43-385A90CF4AFC Q35171432-34ED5B90-FAD4-4D39-91DD-E9E7D9BBB89F Q35585759-3FF87F86-4261-4907-A656-A385372EFFF4 Q35680674-E3CE4B9A-6DFA-457E-B683-530CE91F7C20 Q35742555-E986E7E0-43D2-487E-90C4-BC64C6BEBFDE Q35743233-4FA0B3E0-B351-4AFB-8B1B-7C3F4AD3DADB Q35812195-8F2D72F6-C4C8-4FDA-8BD4-D396451B6A26 Q35852441-28EA99CB-F1D1-4ADD-BAFC-5DCFE506512D Q36072520-171B366E-8B34-4233-9A81-B725055235D3 Q36166107-BE59064E-588A-445F-A507-0C7152AB862D Q36438790-D8C11E00-EC0C-4A61-AEDB-C1AE0F105075 Q36489727-73EB7CF8-E878-4628-BBE9-9F5FE76F5817 Q36535211-CEA6619E-464B-4587-8CF2-25E71CE813F6 Q36843737-E7166AAE-823D-4E17-92CD-CA434B09A731 Q36936972-EBCB0AFA-9626-4289-A90A-D2CA90B4B357 Q37190389-C2E301D3-7C8B-4B11-9006-639D40BCB0B8 Q37619856-22EC2783-07A6-41DC-9872-3574CB4913DB Q37637668-96142039-A902-4D29-8520-5D66DFD88930 Q37651303-1B0D31B6-EC2B-462E-BE2F-5DF2B37BBB9A Q37652863-DEDE9885-7C39-485C-83C2-A905F3608582 Q38236028-67DD75E5-1CE9-477B-8219-560C932F3831 Q38292930-63E5C645-385D-48A8-9E92-F9354D443FD8 Q38387640-D47E6A5F-BA7E-4424-B234-D9CB5C39AFF8 Q38565029-718FCB71-4FAD-451A-B17D-3AA3B2809176 Q38571728-76FF4C70-BBC6-49F1-9ADF-C78B736CBD7B Q38674714-63E436B5-AEEB-4919-81AE-C783FC5A74E7 Q38704025-E7F6D1B0-10AE-44F2-B983-4336E1947456 Q38740840-5EC909EA-6602-415B-86C1-B3F9440E3522

P2860

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

http://www.wikidata.org/entity/Q34367423

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Clinical Pharmacogenetics Impl ...... pe and fluoropyrimidine dosing

@ast

Clinical Pharmacogenetics Impl ...... pe and fluoropyrimidine dosing

@en

Clinical Pharmacogenetics Impl ...... pe and fluoropyrimidine dosing

@nl

type

label

Clinical Pharmacogenetics Impl ...... pe and fluoropyrimidine dosing

@ast

Clinical Pharmacogenetics Impl ...... pe and fluoropyrimidine dosing

@en

Clinical Pharmacogenetics Impl ...... pe and fluoropyrimidine dosing

@nl

prefLabel

Clinical Pharmacogenetics Impl ...... pe and fluoropyrimidine dosing

@ast

Clinical Pharmacogenetics Impl ...... pe and fluoropyrimidine dosing

@en

Clinical Pharmacogenetics Impl ...... pe and fluoropyrimidine dosing

@nl

P1433

Q34367423-4982EFC9-1A70-4F60-B667-93C5C1B92F98

P1476

Q34367423-FB9B79B3-A8D4-48B2-9772-273110E8D517

P2093

Q34367423-03F3D569-1E6F-4CEA-8D82-BEA30C100013

Q34367423-6D841B9F-2CC2-4169-9B67-888D24814EA1

Q34367423-8EA9EB0E-7188-4257-B645-77C8346A9DC9

Q34367423-915FE0C4-5A5D-49C3-9D01-5FA792BAD8FC

Q34367423-AD435105-D1CA-4F99-8BB0-320448E26B60

Q34367423-C9D78D97-F835-4ED2-8647-ACD958D1413D

P2860

Q34367423-020CF1B5-4640-43F1-B443-5801764BD27C

Q34367423-0EA3BE18-311E-4E0F-BF35-F8B180F42676

Q34367423-1AA1EA3E-F702-4BD9-9A1A-A0FC312A1943

Q34367423-207E381D-2B8D-4697-8565-31AC3F8B86B1

Q34367423-2C7A4C64-D388-455C-8FF3-C96E9FE9F257

Q34367423-3DFB504B-89D3-4C79-849A-E8A6614F8DB3

Q34367423-4E426399-EDBB-4A51-81F4-A24059F5DFFC

Q34367423-513213F5-686F-486D-89C0-263AD8EA3581

Q34367423-728D1A6D-8161-4B2F-AAA3-0DBFD429BC7A

Q34367423-72D05EFF-C57F-490E-9204-0F08839D342B

P304

Q34367423-D17FC600-958B-478A-876E-48E50C63A68D

P31

Q34367423-37301D05-672F-4564-BC99-EF239D0EAEC4

P356

Q34367423-A7DF1B04-9DDF-4F72-8D9A-ED9DD8A9EC91

P407

Q34367423-085A3614-0882-4335-8AB8-42F6775551B3

P433

Q34367423-92D7E8F1-7076-4F94-B351-ED0DEDEA6560

P478

Q34367423-596DB511-572E-40AD-A826-B8D3529C6E49

P50

Q34367423-6DBBDE83-1A77-4883-BC4F-80361C6A6557

P577

Q34367423-E124A4EA-99CF-4223-8647-821E105BF5A7

P698

Q34367423-10557D04-3152-4CEA-954C-6EA8A45143EC

P932

Q34367423-D27822B1-6D83-42C6-95BD-C22275396321

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Clinical Pharmacogenetics Impl ...... pe and fluoropyrimidine dosing

@en

P2093

C F Thorn

http://www.w3.org/2001/XMLSchema#string

H L McLeod

http://www.w3.org/2001/XMLSchema#string

K E Caudle

http://www.w3.org/2001/XMLSchema#string

M Schwab

http://www.w3.org/2001/XMLSchema#string

R B Diasio

http://www.w3.org/2001/XMLSchema#string

T E Klein

http://www.w3.org/2001/XMLSchema#string

P2860

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.

Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer.

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.

Pharmacogenetics: from bench to byte--an update of guidelines.

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.

Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.

P304

640-645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2013.172

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23988873

http://www.w3.org/2001/XMLSchema#string

P932

3831181

http://www.w3.org/2001/XMLSchema#string